Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 6.835
Filtrar
1.
Cell Death Dis ; 15(9): 650, 2024 Sep 04.
Artigo em Inglês | MEDLINE | ID: mdl-39231943

RESUMO

Acid sphingomyelinase (ASM) inhibitors are widely used for the treatment of post-stroke depression. They promote neurological recovery in animal stroke models via neurorestorative effects. In a previous study, we found that antidepressants including amitriptyline, fluoxetine, and desipramine increase cerebral angiogenesis post-ischemia/reperfusion (I/R) in an ASM-dependent way. To elucidate the underlying mechanisms, we investigated the effects of the functional ASM inhibitor amitriptyline in two models of I/R injury, that is, in human cerebral microvascular endothelial hCMEC/D3 cells exposed to oxygen-glucose deprivation and in mice exposed to middle cerebral artery occlusion (MCAO). In addition to our earlier studies, we now show that amitriptyline increased mitochondrial reactive oxygen species (ROS) formation in hCMEC/D3 cells and increased ROS formation in the vascular compartment of MCAO mice. ROS formation was instrumental for amitriptyline's angiogenic effects. ROS formation did not result in excessive endothelial injury. Instead, amitriptyline induced a profound metabolic reprogramming of endothelial cells that comprised reduced endothelial proliferation, reduced mitochondrial energy metabolism, reduced endoplasmic reticulum stress, increased autophagy/mitophagy, stimulation of antioxidant responses and inhibition of apoptotic cell death. Specifically, the antioxidant heme oxygenase-1, which was upregulated by amitriptyline, mediated amitriptyline's angiogenic effects. Thus, heme oxygenase-1 knockdown severely compromised angiogenesis and abolished amitriptyline's angiogenic responses. Our data demonstrate that ASM inhibition reregulates a complex network of metabolic and mitochondrial responses post-I/R that contribute to cerebral angiogenesis without compromising endothelial survival.


Assuntos
Amitriptilina , Células Endoteliais , Mitocôndrias , Estresse Oxidativo , Espécies Reativas de Oxigênio , Traumatismo por Reperfusão , Esfingomielina Fosfodiesterase , Animais , Esfingomielina Fosfodiesterase/metabolismo , Mitocôndrias/metabolismo , Mitocôndrias/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Humanos , Traumatismo por Reperfusão/metabolismo , Traumatismo por Reperfusão/patologia , Espécies Reativas de Oxigênio/metabolismo , Amitriptilina/farmacologia , Camundongos , Células Endoteliais/metabolismo , Células Endoteliais/efeitos dos fármacos , Masculino , Camundongos Endogâmicos C57BL , Infarto da Artéria Cerebral Média/complicações , Infarto da Artéria Cerebral Média/patologia , Infarto da Artéria Cerebral Média/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Neovascularização Fisiológica/efeitos dos fármacos , Linhagem Celular , Angiogênese
2.
J Nepal Health Res Counc ; 22(1): 185-191, 2024 Jun 22.
Artigo em Inglês | MEDLINE | ID: mdl-39080958

RESUMO

BACKGROUND: Painful diabetic peripheral neuropathy is one of the frequent presenting complaints in diabetes and endocrine clinics. Our main objective was to compare effectiveness of three commonly prescribed drugs: amitriptyline, pregabalin and duloxetine for treatment of painful diabetic peripheral neuropathy. METHODS: This was a comparative, prospective, observational study conducted among 99 diabetic patients with painful diabetic peripheral neuropathy having numeric rating pain scale ≥ 4. Thirty-three patients in each group were consecutively prescribed amitriptyline, pregabalin and duloxetine in lower dose (10mg/75mg/20mg) for first two weeks to gradually up titrate to higher dose (25mg/150mg/30mg) as per pain response for total duration of eight weeks. RESULTS: At the end of eight weeks, 84.9% in amitriptyline, 78.7% in pregabalin and 60.6% in duloxetine group had adequate pain reduction in form of mild or no pain. Among total patients, 42.5% patients had severe pain at baseline that decreased to 5% by the end of our study. Out of three drugs, 45.5% patients in amitriptyline group had complete resolution of pain as compared to 24.2% in pregabalin and 18.2% in duloxetine group (p value 0.05). Drowsiness (42.4%), dizziness (21.2%) and dry mouth (21.2%) were the commonest side effects among total participants in our study. CONCLUSIONS: Amitriptyline, pregabalin and duloxetine were all associated with adequate pain reduction among patients of painful diabetic peripheral neuropathy in our study, however, amitriptyline had more favorable findings with tolerable side effects.


Assuntos
Amitriptilina , Analgésicos , Neuropatias Diabéticas , Cloridrato de Duloxetina , Pregabalina , Humanos , Cloridrato de Duloxetina/uso terapêutico , Pregabalina/uso terapêutico , Amitriptilina/uso terapêutico , Neuropatias Diabéticas/tratamento farmacológico , Feminino , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Analgésicos/uso terapêutico , Idoso , Adulto , Medição da Dor
3.
Chem Phys Lipids ; 263: 105419, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38964567

RESUMO

Tricyclic medicine such as amitriptyline (AMT) hydrochloride, initially developed to treat depression, is also used to treat neuropathic pain, anxiety disorder, and migraines. The mechanism of functioning of this type of drugs is ambiguous. Understanding the mechanism is important for designing new drug molecules with higher pharmacological efficiency. Hence, in the present study, biophysical approaches have been taken to shed light on their interactions with a model cellular membrane of brain sphingomyelin in the form of monolayer and multi-lamellar vesicles. The surface pressure-area isotherm infers the partitioning of a drug molecule into the lipid monolayer at the air water interface, providing a higher surface area per molecule and reducing the in-plane elasticity. Further, the surface electrostatic potential of the lipid monolayer is found to increase due to the insertion of drug molecule. The interfacial rheology revealed a reduction of the in-plane viscoelasticity of the lipid film, which, depends on the adsorption of the drug molecule onto the film. Small-angle X-ray scattering (SAXS) measurements on multilamellar vesicles (MLVs) have revealed that the AMT molecules partition into the hydrophobic core of the lipid membrane, modifying the organization of lipids in the membrane. The modified physical state of less rigid membrane and the transformed electrostatics of the membrane could influence its interaction with synaptic vesicles and neurotransmitters making higher availability of the neurotransmitters in the synaptic cleft.


Assuntos
Amitriptilina , Antidepressivos Tricíclicos , Esfingomielinas , Esfingomielinas/química , Antidepressivos Tricíclicos/química , Antidepressivos Tricíclicos/farmacologia , Amitriptilina/química , Amitriptilina/metabolismo , Amitriptilina/farmacologia , Espalhamento a Baixo Ângulo , Difração de Raios X , Eletricidade Estática
4.
Skelet Muscle ; 14(1): 16, 2024 Jul 18.
Artigo em Inglês | MEDLINE | ID: mdl-39026344

RESUMO

BACKGROUND: This study aims to investigate the involvement of acid sphingomyelinase (ASM) in the pathology of dermatomyositis (DM), making it a potential therapeutic target for DM. METHODS: Patients with DM and healthy controls (HCs) were included to assess the serum level and activity of ASM, and to explore the associations between ASM and clinical indicators. Subsequently, a myositis mouse model was established using ASM gene knockout and wild-type mice to study the significant role of ASM in the pathology and to assess the treatment effect of amitriptyline, an ASM inhibitor. Additionally, we investigated the potential treatment mechanism by targeting ASM both in vivo and in vitro. RESULTS: A total of 58 DM patients along with 30 HCs were included. The ASM levels were found to be significantly higher in DM patients compared to HCs, with median (quartile) values of 2.63 (1.80-4.94) ng/mL and 1.64 (1.47-1.96) ng/mL respectively. The activity of ASM in the serum of DM patients was significantly higher than that in HCs. Furthermore, the serum levels of ASM showed correlations with disease activity and muscle enzyme levels. Knockout of ASM or treatment with amitriptyline improved the severity of the disease, rebalanced the CD4 T cell subsets Th17 and Treg, and reduced the production of their secreted cytokines. Subsequent investigations revealed that targeting ASM could regulate the expression of relevant transcription factors and key regulatory proteins. CONCLUSION: ASM is involved in the pathology of DM by regulating the differentiation of naive CD4 + T cells and can be a potential treatment target.


Assuntos
Amitriptilina , Diferenciação Celular , Dermatomiosite , Camundongos Knockout , Esfingomielina Fosfodiesterase , Linfócitos T Reguladores , Células Th17 , Dermatomiosite/tratamento farmacológico , Dermatomiosite/imunologia , Dermatomiosite/genética , Humanos , Animais , Diferenciação Celular/efeitos dos fármacos , Masculino , Feminino , Pessoa de Meia-Idade , Células Th17/efeitos dos fármacos , Células Th17/imunologia , Linfócitos T Reguladores/imunologia , Linfócitos T Reguladores/efeitos dos fármacos , Amitriptilina/farmacologia , Amitriptilina/uso terapêutico , Adulto , Camundongos , Esfingomielina Fosfodiesterase/genética , Esfingomielina Fosfodiesterase/metabolismo , Camundongos Endogâmicos C57BL
5.
Eur Rev Med Pharmacol Sci ; 28(10): 3598-3606, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38856135

RESUMO

OBJECTIVE: Painful peripheral diabetic neuropathy (PRDN) is a common disabling condition. Pregabalin and amitriptyline are commonly prescribed as the first-line for PPDN despite the contradicting recommendations. There is a need to inform the scientific community regarding first-line pain control among patients with PPDN. This meta-analysis assessed pregabalin and amitriptyline effects on PPDN. PATIENTS AND METHODS: We searched PubMed, MEDLINE, Cochrane Library, EBSCO, and Google Scholar; the terms used were amitriptyline, pregabalin, painful diabetic neuropathy, antidepressant, gabapentinoids, quality of life, and adverse events. Boolean operators like AND, and OR were used. Six hundred and thirty-one studies were retrieved, and 37 full texts were screened. However, only six randomized controlled trials fulfilled the inclusion and exclusion criteria. RESULTS: No significant statistical differences between amitriptyline and pregabalin regarding pain score and significant pain reduction (odd ratio, -0.82, 95% CI, -2.21-0.58, and odd ratio, 1.16, 95% CI, 0.76-1.76 respectively). Quality of life, total adverse events, and drug discontinuation were not different between the two drugs (odd ratio, 0.89, 95% CI, -2.11-3.89, odd ratio, 0.98, 95% CI, 0.52-1.85, and odd ratio, 0.51, 95% CI, 0.08-3.15, respectively). CONCLUSIONS: No significant statistical differences between amitriptyline and pregabalin regarding their effects on pain and quality of life. The drugs showed similar total adverse events and drug withdrawal. Further larger real-world studies are needed.


Assuntos
Amitriptilina , Analgésicos , Neuropatias Diabéticas , Pregabalina , Pregabalina/uso terapêutico , Pregabalina/efeitos adversos , Pregabalina/administração & dosagem , Amitriptilina/uso terapêutico , Amitriptilina/efeitos adversos , Humanos , Neuropatias Diabéticas/tratamento farmacológico , Analgésicos/uso terapêutico , Analgésicos/efeitos adversos , Qualidade de Vida
6.
Sr Care Pharm ; 39(7): 249-258, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-38937891

RESUMO

Background In older inpatients, anticholinergic medications can increase the risk of complications that may increase length of stay (LOS). Cyclobenzaprine is an anticholinergic medication associated with mental status changes, falls, and injuries in older patients. Objective The purpose of this study is to determine whether use of a lower cyclobenzaprine dose (5 mg) compared with higher dosing (10 mg) will affect LOS, 30-day readmission rates, and need for injectable psychotropic agents in inpatients 65 years of age and older. Methods This was a retrospective cohort analysis comparing outcomes in patients 65 years of age and older who received either a 5 mg or 10 mg cyclobenzaprine dose during their inpatient admission over a 2.5-year period. The primary outcome was hospital LOS, adjusted using multivariate linear regression. Secondary outcomes included 30-day readmission rate adjusted using logistic regression and use of injectable antipsychotics or benzodiazepines. A sub-analysis evaluated the impact of the institution's implementation of a geriatric prescribing context (GEM-CON) on cyclobenzaprine dose selection. Results The adjusted LOS was 32.7% longer (95% CI 25.9%-39.9%) for patients exposed to higher-dose cyclobenzaprine. Use of injectable antipsychotics or benzodiazepines was also significantly greater in the higher-dose group (P < 0.001; P = 0.025). Cyclobenzaprine dose was not significantly associated with readmission on multivariate analysis (OR = 0.93, 95% CI 0.45-1.93). After GEM-CON implementation, there was a significant increase in use of the recommended lower cyclobenzaprine dose (P < 0.001). Conclusion Use of lower cyclobenzaprine dosing in older inpatients is associated with reduced hospital LOS and need for injectable antipsychotics and benzodiazepines.


Assuntos
Amitriptilina , Relação Dose-Resposta a Droga , Tempo de Internação , Readmissão do Paciente , Humanos , Idoso , Estudos Retrospectivos , Masculino , Feminino , Idoso de 80 Anos ou mais , Readmissão do Paciente/estatística & dados numéricos , Amitriptilina/administração & dosagem , Amitriptilina/análogos & derivados , Amitriptilina/efeitos adversos , Pacientes Internados , Antagonistas Colinérgicos/administração & dosagem , Antagonistas Colinérgicos/efeitos adversos , Estudos de Coortes , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos
7.
Acta Derm Venereol ; 104: adv40246, 2024 Jun 25.
Artigo em Inglês | MEDLINE | ID: mdl-38916180

RESUMO

This retrospective study investigates the efficacy of 2 treatment regimens, pregabalin alone versus pregabalin combined with ketamine, amitriptyline, and lidocaine cream, in reducing itch in patients with brachioradial pruritus at a tertiary care center. Electronic medical records of 64 brachioradial pruritus patients seen at the University of Miami Itch Center were analyzed. A significant reduction in itch scores was seen with both treatments, with no significant difference between the groups. A small number of patients experienced adverse effects, including drowsiness and weight gain with pregabalin and skin irritation with ketamine, amitriptyline, and lidocaine cream. Ultimately, our findings underscore the potential of utilizing combined therapy for difficult-to-treat brachioradial pruritus cases and implementing individualized approaches for managing neuropathic pruritus. Further controlled clinical trials are needed to establish optimal treatment protocols.


Assuntos
Amitriptilina , Quimioterapia Combinada , Ketamina , Lidocaína , Pregabalina , Prurido , Centros de Atenção Terciária , Humanos , Estudos Retrospectivos , Prurido/tratamento farmacológico , Prurido/etiologia , Feminino , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Amitriptilina/uso terapêutico , Amitriptilina/efeitos adversos , Lidocaína/administração & dosagem , Lidocaína/uso terapêutico , Ketamina/uso terapêutico , Ketamina/efeitos adversos , Ketamina/administração & dosagem , Pregabalina/uso terapêutico , Idoso , Adulto , Antipruriginosos/uso terapêutico , Antipruriginosos/efeitos adversos , Florida , Creme para a Pele , Administração Cutânea , Registros Eletrônicos de Saúde
8.
Ecotoxicol Environ Saf ; 281: 116656, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38945099

RESUMO

Antidepressant drugs (ADDs) are one of the most extensively used pharmaceuticals globally. They act at particularly low therapeutic concentrations to modulate monoamine neurotransmission, which is one of the most evolutionary conserved pathways in both humans and animal species including invertebrates. As ADDs are widely detected in the aquatic environment at low concentrations (ng/L to low µg/L), their potential to exert drug-target mediated effects in aquatic species has raised serious concerns. Amitriptyline (AMI) is the most widely used tricyclic ADD, while monoamines, the target of ADDs, are major bioregulators of multiple key physiological processes including feeding, reproduction and behaviour in molluscs. However, the effects of AMI on feeding, reproduction and mating behaviour are unknown in molluscs despite their ecological importance, diversity and reported sensitivity to ADDs. To address this knowledge gap, we investigated the effects of environmentally relevant concentrations of AMI (0, 10, 100, 500 and 1000 ng/L) on feeding, reproduction and key locomotor behaviours, including mating, in the freshwater gastropod, Biomphalaria glabrata over a period of 28 days. To further provide insight into the sensitivity of molluscs to ADDs, AMI concentrations (exposure water and hemolymph) were determined using a novel extraction method. The Fish Plasma Model (FPM), a critical tool for prioritization assessment of pharmaceuticals with potential to cause drug target-mediated effects in fish, was then evaluated for its applicability to molluscs for the first time. Disruption of food intake (1000 ng/L) and reproductive output (500 and 1000 ng/L) were observed at particularly low hemolymph levels of AMI, whereas locomotor behaviours were unaffected. Importantly, the predicted hemolymph levels of AMI using the FPM agreed closely with the measured levels. The findings suggest that hemolymph levels of AMI may be a useful indicator of feeding and reproductive disruptions in wild population of freshwater gastropods, and confirm the applicability of the FPM to molluscs for comparative pharmaceutical hazard identification.


Assuntos
Amitriptilina , Antidepressivos Tricíclicos , Água Doce , Reprodução , Poluentes Químicos da Água , Animais , Poluentes Químicos da Água/toxicidade , Reprodução/efeitos dos fármacos , Amitriptilina/toxicidade , Antidepressivos Tricíclicos/toxicidade , Comportamento Alimentar/efeitos dos fármacos , Comportamento Sexual Animal/efeitos dos fármacos
9.
Cell Biol Int ; 48(9): 1326-1342, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38890788

RESUMO

Chronic stress is a universal condition commonly associated with many psychiatric diseases. An extensive body of evidence discussed hippocampal affection upon chronic stress exposure, however, the underlying molecular pathways still need to be identified. We investigated the impact of chronic stress on miR200/BMP/Olig-2 signaling and hippocampal myelination. We also compared the effects of chronic administration of amitriptyline and cholecalciferol on chronically stressed hippocampi. Both amitriptyline and cholecalciferol significantly decreased serum cortisol levels, reduced immobility time in the forced swim test, increased the number of crossed squares in open field test, decreased the hippocampal expression of bone morphogenetic protein 4 (BMP4) and its messenger RNA (mRNA) levels, reduced miR200 expression as compared to untreated chronically stressed rats. Also, both drugs amended the hippocampal neuronal damage, enhanced the surviving cell count, and increased the pyramidal layer thickness of Cornu Ammonis subregion 1 (CA1) and granule cell layer of the dentate gyrus. Cholecalciferol was more effective in increasing the area percentage of myelin basic protein (MBP) and Olig-2 positive cells count in hippocampi of chronic stress-exposed rats than amitriptyline, thus enhancing myelination. We also found a negative correlation between the expression of BMP4, its mRNA, miR200, and the immunoexpression of MBP and Olig-2 proteins. This work underscores the amelioration of the stress-induced behavioral changes, inhibition of miR200/BMP4 signaling, and enhancement of hippocampal myelination following chronic administration of either amitriptyline or cholecalciferol, though cholecalciferol seemed more effective in brain remyelination.


Assuntos
Amitriptilina , Proteína Morfogenética Óssea 4 , Colecalciferol , Hipocampo , MicroRNAs , Transdução de Sinais , Animais , Masculino , Ratos , Amitriptilina/farmacologia , Proteína Morfogenética Óssea 4/metabolismo , Colecalciferol/farmacologia , Hipocampo/metabolismo , Hipocampo/efeitos dos fármacos , MicroRNAs/metabolismo , MicroRNAs/genética , Bainha de Mielina/metabolismo , Bainha de Mielina/efeitos dos fármacos , Ratos Wistar , Transdução de Sinais/efeitos dos fármacos , Estresse Psicológico/metabolismo
10.
Chem Biol Interact ; 397: 111041, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-38719170

RESUMO

Abrocitinib is approved to treat moderate-to-severe atopic dermatitis and eliminated mainly through cytochrome P450 (CYP450) enzyme. Two commonly used antidepressants, amitriptyline and fluoxetine, could inhibit the activities of CYP2C19 and CYP3A4. In this study, we developed a new and quick ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for quantitatively analyzing the plasma concentration of abrocitinib, and further investigated the effects of amitriptyline or fluoxetine on the pharmacokinetics of abrocitinib in rats. The selectivity, linearity, recovery, accuracy, precision, matrix effect and stability of UPLC-MS/MS assay were satisfied according to the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidelines. Our result showed that when co-administered with amitriptyline and fluoxetine, the CLz/F of abrocitinib was reduced by 44.4 % and 33.3 %, respectively, while the AUC(0-t) of abrocitinib was increased by 77.7 % and 49.4 %, respectively. It indicated that amitriptyline and fluoxetine could significantly increase the plasma concentration of abrocitinib in rats. Thus, dose adjustment of abrocitinib may be required when it is combined with amitriptyline or fluoxetine in ongoing clinical practice.


Assuntos
Amitriptilina , Fluoxetina , Ratos Sprague-Dawley , Espectrometria de Massas em Tandem , Animais , Fluoxetina/farmacocinética , Fluoxetina/farmacologia , Ratos , Masculino , Amitriptilina/farmacocinética , Antidepressivos/farmacocinética , Antidepressivos/farmacologia , Cromatografia Líquida de Alta Pressão , Interações Medicamentosas , Pirimidinas/farmacocinética , Pirimidinas/farmacologia , Pirimidinas/sangue
11.
Mikrochim Acta ; 191(6): 336, 2024 05 22.
Artigo em Inglês | MEDLINE | ID: mdl-38777836

RESUMO

A nanocomposite of Ce-doped ZnO/r-GO was synthesized using a conventional hydrothermal method. The synthesized nanocomposites were utilized for the purpose of sensitive and selective detection of cyclobenzaprine hydrochloride (CBP). The properties of the composite were extensively analyzed, including its morphology, structure, and electrochemical behavior. This study investigates the application of a modified glassy carbon electrode for the detection of CBP, a muscle relaxant used to treat musculoskeletal diseases that cause muscle spasms. The electrode is modified with Ce-doped ZnO/r-GO. Various detection methods, such as cyclic voltammetric and square wave techniques (SWV), were utilized. The composite material showed high effectiveness as an electron transfer mediator in the oxidation of CBP. The electrode showed a good response for SWV evaluations in CBP identification, with a minimum detection limit of 1.6 × 10-8 M and a wide linear range from 10 × 10-6 M to 0.6 × 10-7 M, under ideal conditions. The rate constant for charge transfer (ks) and the estimation of the electrochemical active surface area were obtained. A developed sensor exhibited desirable selectivity, long-lasting stability, and remarkable reproducibility. A sensor was used to analyze water, human serum, and urine samples, resulting in positive recovery results.


Assuntos
Amitriptilina , Técnicas Eletroquímicas , Eletrodos , Limite de Detecção , Óxido de Zinco , Óxido de Zinco/química , Técnicas Eletroquímicas/métodos , Técnicas Eletroquímicas/instrumentação , Amitriptilina/química , Amitriptilina/urina , Amitriptilina/sangue , Amitriptilina/análogos & derivados , Nanocompostos/química , Humanos , Relaxantes Musculares Centrais/química , Relaxantes Musculares Centrais/urina , Relaxantes Musculares Centrais/sangue , Relaxantes Musculares Centrais/análise , Reprodutibilidade dos Testes
12.
Chem Res Toxicol ; 37(6): 935-943, 2024 Jun 17.
Artigo em Inglês | MEDLINE | ID: mdl-38761382

RESUMO

Amitriptyline (ATL), a tricyclic antidepressant, has been reported to cause various adverse effects, particularly hepatotoxicity. The mechanisms of ATL-induced hepatotoxicity remain unknown. The study was performed to identify the olefin epoxidation metabolite of ATL and determine the possible toxicity mechanism. Two glutathione (GSH) conjugates (M1 and M2) and two N-acetylcysteine (NAC) conjugates (M3 and M4) were detected in rat liver microsomal incubations supplemented with GSH and NAC, respectively. Moreover, M1/M2 and M3/M4 were respectively found in ATL-treated rat primary hepatocytes and in bile and urine of rats given ATL. Recombinant P450 enzyme incubations demonstrated that CYP3A4 was the primary enzyme involved in the olefin epoxidation of ATL. Treatment of hepatocytes with ATL resulted in significant cell death. Inhibition of CYP3A attenuated the susceptibility to the observed cytotoxicity of ATL. The metabolic activation of ATL most likely participates in the cytotoxicity of ATL.


Assuntos
Amitriptilina , Citocromo P-450 CYP3A , Compostos de Epóxi , Hepatócitos , Microssomos Hepáticos , Ratos Sprague-Dawley , Animais , Amitriptilina/metabolismo , Ratos , Citocromo P-450 CYP3A/metabolismo , Microssomos Hepáticos/metabolismo , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Masculino , Compostos de Epóxi/metabolismo , Compostos de Epóxi/toxicidade , Compostos de Epóxi/química , Glutationa/metabolismo , Células Cultivadas
13.
J Sep Sci ; 47(9-10): e2300949, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38726739

RESUMO

Hydrophilic interaction liquid chromatography (HILIC) has been widely applied to challenging analysis in biomedical and pharmaceutical fields, bridging the gap between normal-phase high-performance liquid chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC). This paper comprehensively explores the retention mechanisms of amitriptyline and its impurities A, B, C, D, F, and G on amide, amino, diol, and silica columns. Dual HILIC/RP-HPLC retention mechanisms were developed, and transitional points between HILIC and RP-HPLC mechanisms were calculated on amide, diol, and silica columns. Adsorption and partition contributions to overall retention mechanisms were evaluated using Python software in HILIC and RP-HPLC regions. The cation exchange mechanism dominates overall retention for ionized analytes in the silica column (R2 > 0.995), whereas the retention of ionized analytes increases with pH. Impacts of acetonitrile content, buffer ionic strength, and pH, along with their interactions on the retention of ionized analytes in the silica column, were determined using the chemometric approach. Acetonitrile content showed the most significant impact on the retention mechanisms. These findings highlight that a detailed investigation into retention mechanisms provides notable insights into factors influencing analyte retention and separation, promising valuable guidance for future analysis.


Assuntos
Amidas , Amitriptilina , Interações Hidrofóbicas e Hidrofílicas , Dióxido de Silício , Dióxido de Silício/química , Amitriptilina/análise , Amitriptilina/química , Amidas/química , Amidas/análise , Cromatografia Líquida de Alta Pressão , Contaminação de Medicamentos , Cromatografia Líquida/métodos , Estrutura Molecular
14.
BMJ ; 385: q871, 2024 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-38692664

RESUMO

The studyFord AC, Wright-Hughes A, Alderson SL, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402:1773-85.To read the full NIHR Alert, go to: https://evidence.nihr.ac.uk/alert/irritable-bowel-syndrome-low-dose-antidepressant-improves-symptoms/.


Assuntos
Amitriptilina , Síndrome do Intestino Irritável , Síndrome do Intestino Irritável/tratamento farmacológico , Humanos , Amitriptilina/administração & dosagem , Amitriptilina/uso terapêutico , Método Duplo-Cego , Antidepressivos/uso terapêutico , Antidepressivos/administração & dosagem , Ensaios Clínicos Controlados Aleatórios como Assunto , Antidepressivos Tricíclicos/administração & dosagem , Antidepressivos Tricíclicos/uso terapêutico , Resultado do Tratamento , Ensaios Clínicos Fase III como Assunto
15.
J Surg Res ; 300: 25-32, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38795670

RESUMO

INTRODUCTION: Previous literature suggests that sphingolipids may impact systemic coagulation and platelet aggregation, thus modulating the risks of thrombotic events. The goal of this investigation was to evaluate the role of serum sphingolipids on intrinsic platelet function to assess whether pharmacologic manipulation of sphingolipid metabolites would impact platelet aggregability. METHODS: C57BL/6J mice were injected with either normal saline, 1 mg/kg FTY720 (synthetic sphingosine-1-phosphate [S1P] receptor analog), or 5 mg/kg SLM6031434 (sphingosine kinase two inhibitor). Mice were sacrificed at 6 h and whole blood (WB) was collected for impedance aggregometry assessing platelet responsiveness to arachidonic acid or adenosine diphosphate. Ex vivo studies utilized WB or platelet-rich plasma that was pretreated with S1P, FTY720, amitriptyline, or d-sphingosine then analyzed by aggregability and flow cytometry for platelet and platelet-derived microvesicle characteristics. RESULTS: FTY720 and SLM6031434 pretreated induced similar arachidonic acid and adenosine diphosphate-mediated platelet aggregation as controls. Ex vivo WB and platelet-rich plasma treatment with S1P, FTY720, amitriptyline and d-sphingosine did not impact platelet aggregation. The percentages of CD41+, CD62P+ and CD41+/ceramide+, CD62P+/ceramide + platelets, and platelet-derived microvesicle were not significantly different between amitriptyline-treated and normal saline-treated cohorts. CONCLUSIONS: Sphingolipid modulating agents, such as FTY720, SLM6031434, S1P, amitriptyline, ceramide, and d-sphingosine do not appear to independently impact platelet aggregation in murine models.


Assuntos
Plaquetas , Cloridrato de Fingolimode , Camundongos Endogâmicos C57BL , Agregação Plaquetária , Esfingolipídeos , Esfingosina , Animais , Agregação Plaquetária/efeitos dos fármacos , Cloridrato de Fingolimode/farmacologia , Esfingosina/análogos & derivados , Esfingosina/sangue , Camundongos , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Esfingolipídeos/sangue , Esfingolipídeos/metabolismo , Masculino , Lisofosfolipídeos/farmacologia , Lisofosfolipídeos/sangue , Fosfotransferases (Aceptor do Grupo Álcool)/metabolismo , Fosfotransferases (Aceptor do Grupo Álcool)/antagonistas & inibidores , Ácido Araquidônico/farmacologia , Amitriptilina/farmacologia , Difosfato de Adenosina/farmacologia
16.
Aerosp Med Hum Perform ; 95(6): 337-340, 2024 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-38790118

RESUMO

BACKGROUND: Functional dyspepsia is a disorder of gut-brain interaction that has the potential to impact aviation performance. Proton pump inhibitors are well-tolerated but are only effective in one half of cases. Second-line treatments, including tricyclic antidepressants, are associated with drowsiness and are not routinely approved for use in aviators. We present a case of a Naval Flight Officer with functional dyspepsia who was successfully treated with amitriptyline and returned to flying status.CASE REPORT: A 23-yr-old male Naval Flight Officer presented with postprandial fullness and epigastric pain. His symptoms were refractory to trials of acid suppression and lifestyle modification. An extensive evaluation by Gastroenterology, including upper endoscopy, did not reveal an organic cause of his symptoms and he was diagnosed with functional dyspepsia. The patient's symptoms resolved with a trial of amitriptyline. Neuropsychological testing demonstrated no medication effect on cognitive performance. A waiver to resume flying duties on amitriptyline was submitted to the Naval Aerospace Medical Institute and was approved.DISCUSSION: We present the second known waiver issued in U.S. Naval aviation history for the use of amitriptyline to treat a gastrointestinal disorder. Amitriptyline is not commonly waived due to the potential for unacceptable cognitive side-effects in the flight environment. However, neuropsychological testing to assess for a possible medication effect on performance can be used to inform an aeromedical disposition and, in this case, allowed for a return to flight status.Crutcher R, Kolasinski N. Functional dyspepsia and tricyclic antidepressant use in a naval flight officer. Aerosp Med Hum Perform. 2024; 95(6):337-340.


Assuntos
Medicina Aeroespacial , Amitriptilina , Antidepressivos Tricíclicos , Dispepsia , Militares , Humanos , Masculino , Antidepressivos Tricíclicos/uso terapêutico , Dispepsia/tratamento farmacológico , Amitriptilina/uso terapêutico , Adulto Jovem
17.
BMJ Case Rep ; 17(4)2024 Apr 16.
Artigo em Inglês | MEDLINE | ID: mdl-38627042

RESUMO

Serotonin syndrome (SS) is a drug-induced clinical syndrome characterised by a combination of cognitive, neuromuscular and autonomic dysfunctions. The symptoms may include mild non-specific symptoms such as tremors and diarrhoea to coma and sudden death. Herein, we describe a case of SS in which acute dizziness was associated with supine hypertension and orthostatic hypotension. A man in his mid-30s had a 10-month history of anxiety, depression and chronic tension-type headache. He had been on amitriptyline (25 mg daily) and sertraline (50 mg daily). Increment of sertraline (75 mg daily) and amitriptyline (75 mg daily) and the addition of tramadol led to the development of acute severe dizziness. Physical examinations demonstrate supine hypertension and orthostatic hypotension. He also met the diagnostic criteria of SS. The administration of cyproheptadine provided a complete response to dizziness, supine hypertension, orthostatic hypotension and other clinical features of SS.


Assuntos
Hipertensão , Hipotensão Ortostática , Síndrome da Serotonina , Masculino , Humanos , Hipotensão Ortostática/complicações , Hipotensão Ortostática/diagnóstico , Hipotensão Ortostática/tratamento farmacológico , Tontura/induzido quimicamente , Tontura/diagnóstico , Síndrome da Serotonina/induzido quimicamente , Síndrome da Serotonina/complicações , Síndrome da Serotonina/diagnóstico , Amitriptilina , Sertralina , Vertigem
18.
Physiol Behav ; 281: 114552, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-38614419

RESUMO

BACKGROUND: Recent research has highlighted the potential role of Helicobacter pylori in the pathogenesis of psychiatric disorders. This study aimed to evaluate the potential synergistic effects of an antidepressant drug and H. pylori eradication therapy in a mouse model. METHODS: Male C57BL/6 mice were divided into four groups: control, H. pylori infection, antidepressant treatment, and combined treatment. H. pylori infection was induced by oral gavage with a clinically relevant strain, and the antidepressant drug was administered via intraperitoneal injections. Behavioral tests including the forced swim test, sucrose preference test, and open field test were conducted to assess depressive-like behaviors and locomotor activity. RESULTS: The study demonstrated that H. pylori infection induced depressive-like behaviors in mice, as evidenced by increased immobility time in the forced swim test and reduced sucrose preference. Antidepressant treatment alone partially ameliorated these behavioral changes. Strikingly, the combined treatment of the antidepressant drug and H. pylori eradication therapy led to a significantly greater reduction in depressive-like behaviors compared to either treatment alone. Furthermore, the combined treatment group exhibited increased locomotor activity in the open field test, suggesting a potential improvement in overall psychomotor functioning. ELISA assays revealed alterations in inflammatory cytokines in the H. pylori-infected mice, which were partially attenuated by the combined treatment. CONCLUSION: The study provides novel evidence for the potential synergistic effects of an antidepressant drug and H. pylori eradication therapy in alleviating depressive-like behaviors in a mouse model.


Assuntos
Amitriptilina , Citocinas , Modelos Animais de Doenças , Infecções por Helicobacter , Helicobacter pylori , Camundongos Endogâmicos C57BL , Animais , Masculino , Infecções por Helicobacter/tratamento farmacológico , Amitriptilina/farmacologia , Amitriptilina/administração & dosagem , Citocinas/metabolismo , Helicobacter pylori/efeitos dos fármacos , Depressão/tratamento farmacológico , Camundongos , Antidepressivos/farmacologia , Antibacterianos/farmacologia , Sinergismo Farmacológico , Atividade Motora/efeitos dos fármacos , Natação
19.
Brain Behav Immun ; 119: 408-415, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38636564

RESUMO

Vestibulodynia is a complex pain disorder characterized by chronic discomfort in the vulvar region, often accompanied by tactile allodynia and spontaneous pain. In patients a depressive behaviour is also observed. In this study, we have used a model of vestibulodynia induced by complete Freund's adjuvant (CFA) focusing our investigation on the spinal cord neurons and microglia. We investigated tactile allodynia, spontaneous pain, and depressive-like behavior as key behavioral markers of vestibulodynia. In addition, we conducted in vivo electrophysiological recordings to provide, for the first time to our knowledge, the characterization of the spinal sacral neuronal activity in the L6-S1 dorsal horn of the spinal cord. Furthermore, we examined microglia activation in the L6-S1 dorsal horn using immunofluorescence, unveiling hypertrophic phenotypes indicative of neuroinflammation in the spinal cord. This represents a novel insight into the role of microglia in vestibulodynia pathology. To address the therapeutic aspect, we employed pharmacological interventions using GABApentin, amitriptyline, and PeaPol. Remarkably, all three drugs, also used in clinic, showed efficacy in alleviating tactile allodynia and depressive-like behavior. Concurrently, we also observed a normalization of the altered neuronal firing and a reduction of microglia hypertrophic phenotypes. In conclusion, our study provides a comprehensive understanding of the CFA-induced model of vestibulodynia, encompassing behavioral, neurophysiological and neuroinflammatory aspects. These data pave the way to investigate spinal cord first pain plasticity in vestibulodynia.


Assuntos
Modelos Animais de Doenças , Adjuvante de Freund , Hiperalgesia , Microglia , Neurônios , Medula Espinal , Vulvodinia , Animais , Medula Espinal/metabolismo , Medula Espinal/fisiopatologia , Camundongos , Hiperalgesia/fisiopatologia , Hiperalgesia/metabolismo , Vulvodinia/fisiopatologia , Vulvodinia/metabolismo , Feminino , Microglia/metabolismo , Neurônios/metabolismo , Doenças Neuroinflamatórias/fisiopatologia , Gabapentina/farmacologia , Amitriptilina/farmacologia , Depressão/fisiopatologia , Depressão/metabolismo , Camundongos Endogâmicos C57BL
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA